Participants:
• Adults with a physician-confirmed diagnosis of psoriasis, not in a clinical trial and working for pay outside the home or not working for pay outside the home due to psoriasis were recruited for the study.
• Participants recruited were stratified according to PASI score, with a target of 40 patients per category:
• Mild: PASI≤3
• Moderate: 3<PASI≤12
• Moderate/severe: 12<PASI≤20 • Severe: PASI>20
Data Collection:
• Participants completed a survey of demographic and clinical questions, and various patient-reported outcome measures.
• Medical chart data from eligible participants were extracted to collect clinical information, including the physician's assessment of severity at the time of the survey.
• Severity was assessed using the BSA, modified IGA, and PASI.
• The BSA requires the physician to estimate the percentage of body area affected by psoriasis and to indicate if psoriasis is present on the following areas: hands/feet, face, genitals, limbs, and/or trunk.
• The IGA MOD 2011 rating scale for overall psoriatic disease is shown in Table 1 . 2 • The PASI assesses the redness, thickness and scale of the psoriasis lesions, on a scale from 0 (none) to 4 (severe) for each of these attributes. The percentage of skin covered by psoriasis is also scored on a scale from 0 (0%) to 6 (90-100%). This is done for each of the trunk, head, arms and legs, and the scores are weighted by the location of psoriasis. 2
Analysis:
• Mean, standard deviation (SD), median and interquartile range (IQR) were calculated for the BSA. The number and proportion of patients with each of the specified areas affected was tabulated.
• The number and proportion of participants with each of the IGA categorical scores was tabulated.
• The BSA and IGA results are presented for the total study sample and by PASI category.
• Correlation between disease severity measures was assessed using the Spearman rank correlation.
Correlation of Severity Measures:
• All measures were significantly correlated with one another (p < 0.00; Figure 1 ).
• The BSA and PASI were the most closely correlated measures (r=0.91), followed by the PASI and the IGA (r=0.83) and then the BSA and IGA (r=0.77).
• The PASI was also significantly correlated with the number of body areas where psoriasis is present, as recorded within the BSA (r=61; p<0.001).
• The data from this observational study indicate that the PASI, BSA and IGA severity measures closely align in their assessment of psoriasis severity.
• These data enable the comparison of patient samples assessed using different severity measures in the diagnosis and the assessment of treatment effectiveness of psoriasis in the real world setting.
• There was no clear trend between location of psoriasis based on the BSA measure and PASI severity. This is likely due to the majority of the study sample having psoriasis on their legs which is given the highest weighting in the PASI assessment.
• A key limitation of this study is the limited number of severe patients included.
• Only 21 out of 40 target patients were recruited in the PASI category >20.
• Two sites noted that more severe patients were often in clinical trials, thus not eligible for this study.
• Additionally, many of the patients in with severe disease were from one study site, thus limiting the generalizability of the results.
• Further research among a larger patient sample with severe disease would be required to ascertain the correlation of these severity measures among more severe cases. Table 3 . Physician-reported assessment of BSA and affected areas at study enrolment for continuous variables for the overall study sample, stratified by PASI category Figure 1 . Assessment of severity using the BSA, PASI and IGA measures.
• Psoriasis is a chronic inflammatory skin condition with symptoms including raised, red, scaly patches typically appearing on the elbows, knees and/or scalp. 1
• The severity of psoriasis symptom can be assessed through a variety of measures.
• The percentage of body surface area (BSA) affected is a common approach used in clinical settings. The BSA also considers the location of the psoriasis.
• The investigator global assessment (IGA) is another common approach used in clinical practice. This approach takes into consideration the clinical presentation of the disease from the physician perspective, using five categories of severity. 2 • The Psoriasis Area and Severity Index (PASI) score is widely used in clinical trials and accepted by approving agencies and other decision makers. 2 The PASI measures severity on a scale of increasing severity from 0 to 72.
• Comparisons across studies are difficult without a clear understanding of how the different severity measures correlate.
• Additionally, it is important for clinicians to understand how the measures used in routine clinical practice correlate with measures commonly used in clinical trials.
• This study assessed the correlation of the PASI, BSA, and the modified IGA (IGA MOD), scale; all of which assess psoriasis disease severity.
Severity Assessments:
• The mean (SD) BSA was 10.9% (11.7%) for the total study sample (Table 3 ).
• The mean BSA increased according to the PASI category:
• 2.2% among patients in the mild PASI category; • 5.8% among patients in the moderate PASI category; • 6.2% among patients in the moderate/severe PASI category; and • 27.3% among patients in the severe PASI category.
• The limbs were the most frequently affected area, with 93% of patients affected.
• The genitals were the least frequently affected area, with 18.3% of patients affected.
• No pattern was observed between affected area and PASI category. 
